Skip to main content



26-11-2020 | Rheumatology | News | Article

Further evidence against hydroxychloroquine use for prevention, treatment of COVID-19

Findings from two randomized trials provide further evidence to suggest that hydroxychloroquine has no benefits for the prevention or treatment of COVID-19.

25-11-2020 | Rheumatology | News | Article

Methotrexate discontinuation may be feasible in PsA patients treated with tofacitinib

Patients with psoriatic arthritis undergoing stable treatment with tofacitinib plus methotrexate may be able to withdraw methotrexate without having an adverse impact on disease activity, suggests a substudy of the OPAL Balance trial.

23-11-2020 | Rheumatology | News | Article

No reduction in COVID-19 mortality risk with routine hydroxychloroquine use in RMD patients

Use of hydroxychloroquine for the treatment of rheumatic and musculoskeletal diseases is not associated with a reduction in COVID-19 mortality risk, suggest findings from an observational study published in The Lancet Rheumatology.

20-11-2020 | Rheumatology | News | Article

FDA authorizes baricitinib combination for COVID-19

Click through for more information on this Emergency Use Authorization

19-11-2020 | Rheumatology | News | Article

Intensive acupuncture may improve pain, function in knee osteoarthritis

An 8-week intensive course of electro-acupuncture could improve pain and function in patients with knee osteoarthritis, with the effects lasting for up to 26 weeks, Chinese research shows.

17-11-2020 | Rheumatology | News | Article

Mixed results for prednisolone in axial spondyloarthritis

Treatment with oral prednisolone on a step-down regimen may reduce disease activity in people with axial spondyloarthritis but has minimal impact on other outcomes such as functional improvement, Indian researchers report.

16-11-2020 | Rheumatology | News | Article

Meta-analysis queries VTE risk associated with JAK inhibitors in clinical trials

A meta-analysis of randomized controlled trials has found no significant association between Janus kinase inhibitor use and the risk for venous thromboembolism among patients with immune-mediated inflammatory diseases.

11-11-2020 | Rheumatology | News | Article

​​​​​​​BIIB059 shows potential for cutaneous lupus erythematosus

Findings from the second part of the LILAC trial suggest that BIIB059, a monoclonal antibody targeting blood dendritic cell antigen 2, improves skin outcomes for patients with active cutaneous lupus erythematosus.

11-11-2020 | Rheumatology | News | Article

‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

11-11-2020 | Rheumatology | News | Article

​​​​​​​Early findings encouraging for deucravacitinib in psoriatic arthritis

Deucravacitinib, a novel selective tyrosine kinase 2 inhibitor, may be a promising treatment option for patients with psoriatic arthritis, suggest phase 2 data presented in a poster at the ACR Convergence 2020 virtual meeting.

11-11-2020 | Rheumatology | News | Article

Survey sheds light on rheumatology provider experiences during COVID-19 pandemic

A survey of Veterans Affairs rheumatology consortium members has given greater insight into the experiences and opinions of rheumatology providers during the COVID-19 pandemic.

11-11-2020 | Rheumatology | News | Article

​​​​​​​Ziritaxestat warrants further investigation in early diffuse cutaneous systemic sclerosis

The autotaxin inhibitor ziritaxestat may improve skin fibrosis in patients with early diffuse cutaneous systemic sclerosis, show data from the phase 2a NOVESA study presented at the ACR Convergence 2020 virtual meeting.

11-11-2020 | Rheumatology | News | Article

Evobrutinib fails to improve response rate in refractory RA patients

Evobrutinib does not improve treatment response in patients with rheumatoid arthritis who do not respond adequately to methotrexate, phase IIb study data indicate.

10-11-2020 | Rheumatology | News | Article

Phase 3 trial demonstrates benefits of tofacitinib in ankylosing spondylitis

The JAK inhibitor tofacitinib is a promising treatment option for people with ankylosing spondylitis, suggest phase 3 trial findings presented at the ACR Convergence 2020 virtual meeting.

10-11-2020 | Rheumatology | News | Article

Reduced flare risk with mavrilimumab in giant cell arteritis

Mavrilimumab is effective for reducing the risk for flare and maintaining sustained remission in patients with giant cell arteritis, phase 2 study findings show.

09-11-2020 | Rheumatology | News | Article

FAST: No increase in cardiovascular risk with febuxostat vs allopurinol

Among patients with gout, those who receive febuxostat treatment do not have a higher risk for cardiovascular events than those on allopurinol, according to the results of the FAST trial.

09-11-2020 | Rheumatology | News | Article

COVID-19 may be rare in children with rheumatic diseases

COVID-19 is uncommon in children with rheumatic diseases and appears to result in mild illness when it occurs, suggest data presented at the ACR Convergence 2020 virtual meeting.

09-11-2020 | Rheumatology | News | Article

Pregnancy does not impact COVID-19 outcomes in women with rheumatic diseases

Research presented at the ACR Convergence 2020 virtual meeting provides reassurance that pregnant women with rheumatic diseases can expect a favorable outcome if they develop COVID-19.

09-11-2020 | Rheumatology | News | Article

​​​​​​​Biologic therapy linked to increased shielding during COVID-19 pandemic

Patients with rheumatic diseases taking biologic therapy were more likely to shield during the first 6 months of the COVID-19 pandemic than those taking other drug types, shows research reported at the ACR Convergence 2020 virtual meeting.

09-11-2020 | Rheumatology | News | Article

COVID-19 cited as reason for making medication changes by patients with RA

Patients with rheumatoid arthritis from the USA made substantial changes to their medication use during the first few months of the COVID-19 pandemic, research shows.

Image Credits